Posts

BioMarin buys early-stage oral bone-disease drug from Alesta

on
BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in development and regulatory milestone payments. The deal gives BioMarin ALE1, an oral small-molecule candidate for hypophosphatasia (HPP), a rare genetic bone disease caused by ALPL mutations. ALE1 is in an ongoing Phase 1/2a trial and could become the first oral treatment for HPP, potentially offering an alternative to current injectable therapies. Although announced as an acquisition, it is effectively an asset-focused transaction: Alesta plans to spin out its other programs and employees into a separate company before closing. The transaction is expected to close in the third quarter of 2026 and will be funded with BioMarin’s cash on hand. Sources: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential ... BioMarin snaps up Alesta's lead asset for $275M - pharmaphorum BioMarin does another small deal to get early-stage bone disease ... BioMarin inks $...

Trump claims credit for falling drug prices, but Biden-era Medicare negotiations likely played a major role

on

Cortechs.ai Wins FDA Clearance for NeuroQuant PET

on

WHOOP opens Advanced Labs to non-members and adds GRAIL’s Galleri cancer test

on

Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars

on

EyePoint Shares Crash After Duravyu Phase 3 Stumble in Wet AMD, But Treatment Burden Reduction Shines

on

Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in Phase 3 win

on

Third patient death revealed in China's CAR-T and gene therapy trials, spotlighting IIT safety and transparency

on

Regeneron ends eye disease trial for anti-CD3 antibody following safety review – 2026 update

on

Sandoz Licenses Three Biosimilar Drugs From Shanghai Henlius Biotech in Up To $322 Million Deal

on

Lilly to Pay Up to $370M for OmniAb Collaboration

on

EyePoint's bid to compete with Eylea falls flat after Phase 3 wet AMD setback

on

Argenx moves toward FDA submission with Vyvgart after Phase 3 success in autoimmune myositis indication

on